VISTAGEN THERAPEUTICS INC

Vistagen insiders buy shares at a discount, signaling confidence in its Phase 3 anti‑arthritis drug and strong 2027 liquidity, hinting at future upside.

Vistagen Therapeutics insider buying sparks investor interest—CFO’s recent $0.19 share purchase amid a failed Phase 3 trial hints at confidence, but watch regulatory updates and cash runway for full outlook.

Vistagen’s coordinated incentive‑stock option grants signal executive confidence amid volatile biotech markets—unlocking value potential as regulatory milestones loom.

Vistagen’s insider option grants signal executive confidence in its CNS therapeutics, outlining how equity, cash‑sparing strategy, and digital‑health partnerships could drive post‑milestone growth and valuation.